AnavexLife Sciences, a leading biopharmaceutical company, has recently announced promising findings from the 48-week, open-label extension of its phase 2 study involving blarcamesine. Blarcamesine, also known as ANAVEX2-73, has shown significant potential in the treatment of Parkinson disease dementia (PDD). Despite the challenges posed by the COVID-19 pandemic, the study demonstrated that patients who continued […]
Continue reading